期刊名称：Proceedings of the National Academy of Sciences
印刷版ISSN：0027-8424
电子版ISSN：1091-6490
出版年度：2020
卷号：117
期号：48
页码：30025-30026
DOI：10.1073/pnas.2009253117
出版社：The National Academy of Sciences of the United States of America
摘要：COVID-19 is one of the largest pandemics ever faced, and the current lack of specific and effective therapeutics has led to significant morbidity and mortality. Multiple existing drugs have been repurposed and tested in clinical trials. However, without preclinical studies, their mechanisms in combating COVID-19 are speculative, and their efficacy and safety remains largely unknown. Unexpected side effects have been reported, and, as a result, some of these trials have been terminated. Tocilizumab (TCZ) is a recombinant humanized anti-human IL-6 receptor (IL-6R) monoclonal antibody. It can bind to IL-6R with high affinity, preventing IL-6 from binding, thereby reducing immune damage to target cells. Xu et al.
